Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diphenhydramine HCl Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

NCT05627557
View directory record Official record
Conditions
Childhood Idiopathic Nephrotic Syndrome
Interventions
Obinutuzumab, MMF, Prednisone, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Palo Alto, California • Hollywood, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

NCT03142165
View directory record Official record
Conditions
Fibrosis
Interventions
BMS-986263, Placebo, Diphenhydramine, Famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 4 Interventional Results available

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

NCT02657031
View directory record Official record
Conditions
Headache
Interventions
Prochlorperazine, Ketamine, Diphenhydramine, Ondansetron, Normal Saline
Drug
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 5, 2026, 5:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

NCT06207305
View directory record Official record
Conditions
Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
Interventions
Dexamethasone, Diphenhydramine, Famotidine, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 5, 2026, 5:49 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

NCT01712828
View directory record Official record
Conditions
Healthy
Interventions
Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 5, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

NCT03459612
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo, Diphenhydramine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

NCT00618826
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

NCT01666678
View directory record Official record
Conditions
Therapeutic Equivalence
Interventions
BAY98-7111, Naproxen Sodium (Aleve, BAYH6689), Diphenhydramine HCl
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 5, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
Drug
Lead sponsor
Benjamin T Diamond, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Therapies for Down Syndrome Regression Disorder

NCT05662228
View directory record Official record
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

NCT02935699
View directory record Official record
Conditions
Acute Urticaria
Interventions
Test Drug (JDP-205), Active Control (Diphenhydramine)
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

NCT04862585
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Cimetidine, Dexamethasone, Diphenhydramine, Famotidine, Paclitaxel, Quality-of-Life Assessment, Ranitidine
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

NCT03598426
View directory record Official record
Conditions
Hypersensitivity Reactions
Interventions
Dexamethasone
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 5, 2026, 5:49 PM EDT
Terminated Early Phase 1 Interventional

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

NCT01276613
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Losartan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 5, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 5, 2026, 5:49 PM EDT